Triple-negative breast cancer is an especially challenging subtype characterized by the absence of key receptors, limiting the effectiveness of many standard breast cancer treatments.
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. reported the discovery of SHR-3591, an orally bioavailable AR proteolysis targeting chimera (PROTAC) designed to treat prostate tumors.
Aiming to develop a systemic therapy for advanced refractory cancers, researchers have designed a novel oncolytic adenovirus that selectively targets and kills cancer cells expressing mesothelin.
PARP inhibitors have been approved for the treatment of several cancers, including ovarian, breast, pancreatic and prostate cancers with BRCA mutations or other homologous recombination repair deficiencies (HRD). However, their therapeutic potential is limited by challenges such as hematologic toxicity and lack of target selectivity.
Starg (Wuhan) Pharmaceutical Technology Co. Ltd. has described Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Shanghai Yiweikang Pharmaceutical Co. Ltd. has divulged camptothecin derivatives acting as DNA topoisomerase I inhibitors reported to be useful for the treatment of cancer.
Haisco Pharmaceutical Group Co. Ltd. has identified peptide-drug conjugates comprising a peptide targeting integrin αvβ3 (vitronectin) covalently bound to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Revolution Medicines Inc. has disclosed macrocyclic compounds acting as GTPase KRAS (G12V mutant) inhibitors reported to be useful for the treatment of cancer.
Human papillomavirus (HPV), particularly the high-risk HPV16 subtype, is a major driver of certain cancers, including cervical, oropharyngeal, anal and penile cancers. The E6 and E7 proteins produced by HPV16 are known to play critical roles in the development of these malignancies, making them attractive targets for therapeutic interventions.
RSS
